Program
GDC-1261
A development code.
Its studies are mostly in Prostatic Neoplasms, led by Hoffmann-La Roche.
Furthest: phase 2, since Apr 13, 20261 company-led study, 1 open or runningNext primary completion: Nov 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 11 open or running | phase 2since Apr 13, 2026 | Apr 13, 2026 | Nov 30, 2027phase 2 · NCT07567846 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 13, 2026First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT07567846 · 260 planned · United States, Australia, United Kingdom
Ahead
- Nov 30, 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07567846
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07567846Prostatic Neoplasms · United States, Australia, United Kingdom | 2 | Recruiting | Nov 30, 2027 | 260 |
How it is read
Names in the registry
- “GDC-1261”, 1 entry
Codes read as this program: GDC1261.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.